Management of post-chemotherapy residual masses in advanced seminoma

被引:62
|
作者
Fléchon, A [1 ]
Bompas, E [1 ]
Biron, P [1 ]
Droz, JP [1 ]
机构
[1] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
来源
JOURNAL OF UROLOGY | 2002年 / 168卷 / 05期
关键词
testes; seminoma; drug therapy; cisplatin; neoplasm; residual;
D O I
10.1016/S0022-5347(05)64275-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We studied the resection of post-chemotherapy residual masses (20% to 80%) of advanced seminoma complicated by extensive fibrosis, in which active disease appears in 10% to 20% of cases. Materials and Methods: We retrospectively analyzed (1986 to 2000) residual mass evolution according to size in 79 platinum treated patients. Results: There was an evaluable response in 78 patients, including toxic death in 1 after 1 chemotherapy cycle, a complete response in 34 (after chemotherapy in 15 and after complete residual mass resection in 19), a marker negative partial response in 42 (incomplete residual mass resection in 8), stable and progressive disease in 1 each. In 15 of 31 patients the resected residual mass was 3 cm. or greater, whereas in 12 of 29 it was less than 3 cm. No surgery was performed for 3 residual masses of unknown size. Of the 42 residual masses 21 disappeared at a median of 12.5 months. Progression occurred at the initial tumor site in 11 of 13 patients after a median of 3.5 months, including 3 with a complete response, 8 with a marker negative partial response (residual mass 3 cm. or greater in 3, less than 3 cm. in 4 and unknown size in 1) and treatment failure in 2 (residual mass 3 cm. or greater). At a median followup of 36.4 months 67 patients survived (no disease progression in 56 and nonevolving residual masses in 11), while 12 had died including 9 of progressive disease 1 of toxicity and 2 of other causes. Conclusions: In our study there was incomplete surgical resection in 30% of cases. Relapse in 16.6% of cases occurred rapidly after the end of chemotherapy. Viable cells were only noted in residual masses 3 cm. or greater (13%) and 50% of residual masses disappeared during surveillance. We intend. to perform a prospective cohort study with close followup of patients with residual masses less than 3 cm. using an indication for surgery tailored to positron emission tomography findings in those with residual masses 3 cm. or greater.
引用
收藏
页码:1975 / 1979
页数:5
相关论文
共 50 条
  • [31] Laparoscopic post-chemotherapy retroperitoneal dissection of residual mass
    Bales, GT
    Gerber, GS
    Rukstalis, DB
    BRITISH JOURNAL OF UROLOGY, 1997, 80 (02): : 349 - 350
  • [32] Optimal management of residual mass after chemotherapy in advanced seminoma: There is time for everything - Reply
    Motzer, RJ
    Herr, H
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2885 - 2885
  • [33] FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma
    Gallamini, Andrea
    Kurlapski, Michal
    Zaucha, Jan Maciej
    CANCERS, 2021, 13 (16)
  • [34] Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography- Computed Tomography-Based Risk-adapted Approach
    Murthy, V.
    Karmakar, S.
    Carlton, J.
    Joshi, A.
    Krishnatry, R.
    Prabhash, K.
    Noronha, V.
    Bakshi, G.
    Prakash, G.
    Pal, M.
    Menon, S.
    Agrawal, A.
    Rangarajan, V.
    CLINICAL ONCOLOGY, 2021, 33 (07) : e315 - e321
  • [35] Survival Analysis of Pure Seminoma at Post-Chemotherapy Retroperitoneal Lymph Node Dissection
    Rice, Kevin R.
    Beck, Stephen D. W.
    Bihrle, Richard
    Cary, K. Clint
    Einhorn, Lawrence H.
    Foster, Richard S.
    JOURNAL OF UROLOGY, 2014, 192 (05): : 1397 - 1402
  • [36] False Positive 2-18Fluroro-deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients With Disseminated Seminoma and Post-Chemotherapy Residual Masses
    Wagner, Mathilde
    Bellmunt, Joaquim
    Boutros, Celine
    Bonardel, Gerald
    Loriot, Yohann
    Albiges, Laurence
    Massard, Christophe
    Fizazi, Karim
    CLINICAL GENITOURINARY CANCER, 2013, 11 (01) : 66 - 69
  • [37] Re: The Role of Positron Emission Tomography in the Evaluation of Residual Masses After Chemotherapy for Advanced Stage Seminoma Reply
    Hinz, S.
    Schrader, M.
    Kempkensteffen, C.
    Bares, R.
    Brenner, W.
    Krege, S.
    Franzius, C.
    Kliesch, S.
    Heicappel, R.
    Miller, K.
    de Wit, M.
    JOURNAL OF UROLOGY, 2008, 180 (06): : 2718 - 2718
  • [38] Can tumor-to-liver (T/L) ratio predict progression free survival in patients with post-chemotherapy seminoma residual
    Ghosh, S.
    Agrawal, A.
    Rangarajan, V.
    Choudhury, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S149 - S149
  • [39] TREATMENT OF THE RESIDUAL RETROPERITONEAL MASS AFTER CHEMOTHERAPY FOR ADVANCED SEMINOMA
    ELLISON, MF
    MOSTOFI, FK
    FLANIGAN, RC
    JOURNAL OF UROLOGY, 1988, 140 (03): : 618 - 620
  • [40] Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis
    Fitzgerald, John P.
    Ercole, Barbara
    Parekh, Dipen J.
    INDIAN JOURNAL OF UROLOGY, 2010, 26 (01) : 98 - 101